JP2011518194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518194A5 JP2011518194A5 JP2011505263A JP2011505263A JP2011518194A5 JP 2011518194 A5 JP2011518194 A5 JP 2011518194A5 JP 2011505263 A JP2011505263 A JP 2011505263A JP 2011505263 A JP2011505263 A JP 2011505263A JP 2011518194 A5 JP2011518194 A5 JP 2011518194A5
- Authority
- JP
- Japan
- Prior art keywords
- shal
- linker
- ligand
- phenoxy
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims description 71
- -1 (3-chloro-5 (trifluoromethyl) pyridin-2-yloxy) phenoxy Chemical group 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 24
- 239000012636 effector Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 20
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 235000019260 propionic acid Nutrition 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 239000013522 chelant Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 108090001008 Avidin Proteins 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 10
- SIEKBQPWGCCNGS-UHFFFAOYSA-N 3-[2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyanilino]-3-oxopropanoic acid Chemical compound OC(=O)CC(=O)NC1=CC=CC=C1OC1=NC=C(C(F)(F)F)C=C1Cl SIEKBQPWGCCNGS-UHFFFAOYSA-N 0.000 claims description 8
- KSDVAPCASJRMAD-UHFFFAOYSA-N 4-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-3-nitrobenzoic acid Chemical compound [O-][N+](=O)C1=CC(C(=O)O)=CC=C1N1CCN(CC=2C=CC(Cl)=CC=2)CC1 KSDVAPCASJRMAD-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- YUVKUEAFAVKILW-UHFFFAOYSA-N 2-(4-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=CC=C(C(F)(F)F)C=N1 YUVKUEAFAVKILW-UHFFFAOYSA-N 0.000 claims description 6
- OOLBCHYXZDXLDS-UHFFFAOYSA-N 2-[4-(2,4-dichlorophenoxy)phenoxy]propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=CC=C(Cl)C=C1Cl OOLBCHYXZDXLDS-UHFFFAOYSA-N 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 239000000412 dendrimer Substances 0.000 claims description 6
- 229920000736 dendritic polymer Polymers 0.000 claims description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 6
- XKHPEMKBJGUYCM-UHFFFAOYSA-N ethyl 2-oxochromene-3-carboxylate Chemical compound C1=CC=C2OC(=O)C(C(=O)OCC)=CC2=C1 XKHPEMKBJGUYCM-UHFFFAOYSA-N 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- PWXJULSLLONQHY-UHFFFAOYSA-N phenylcarbamic acid Chemical compound OC(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-N 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- MPPOHAUSNPTFAJ-UHFFFAOYSA-N 2-[4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy]propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=NC2=CC=C(Cl)C=C2O1 MPPOHAUSNPTFAJ-UHFFFAOYSA-N 0.000 claims description 4
- 101710112752 Cytotoxin Proteins 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 4
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- YUIKUTLBPMDDNQ-MRVPVSSYSA-N clodinafop Chemical compound C1=CC(O[C@H](C)C(O)=O)=CC=C1OC1=NC=C(Cl)C=C1F YUIKUTLBPMDDNQ-MRVPVSSYSA-N 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 4
- 239000002619 cytotoxin Substances 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 4
- 230000026683 transduction Effects 0.000 claims description 4
- 238000010361 transduction Methods 0.000 claims description 4
- 229960004295 valine Drugs 0.000 claims description 4
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 3
- CZKNFPFWQYDPKT-UHFFFAOYSA-N ClC1=CC(C(F)(F)F)=CN=C1OC1=CC=CC=C1CC(=C)C#N Chemical compound ClC1=CC(C(F)(F)F)=CN=C1OC1=CC=CC=C1CC(=C)C#N CZKNFPFWQYDPKT-UHFFFAOYSA-N 0.000 claims description 3
- QVVDVENEPNODSI-BTNSXGMBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylidene Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QVVDVENEPNODSI-BTNSXGMBSA-N 0.000 claims description 2
- OZRPKALPSGYEHX-UHFFFAOYSA-N 2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenylpyrrole-3-carboxylic acid Chemical compound C1COCCN1CCCN1C(C)=C(C(O)=O)C=C1C1=CC=CC=C1 OZRPKALPSGYEHX-UHFFFAOYSA-N 0.000 claims description 2
- ABOOPXYCKNFDNJ-UHFFFAOYSA-N 2-{4-[(6-chloroquinoxalin-2-yl)oxy]phenoxy}propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=CN=C(C=C(Cl)C=C2)C2=N1 ABOOPXYCKNFDNJ-UHFFFAOYSA-N 0.000 claims description 2
- JEFTWCWADIIOMX-UHFFFAOYSA-N 3-[3-chloro-2-[5-(trifluoromethyl)pyridin-2-yl]oxyanilino]-3-oxopropanoic acid Chemical compound ClC=1C(=C(NC(CC(=O)O)=O)C=CC1)OC1=NC=C(C=C1)C(F)(F)F JEFTWCWADIIOMX-UHFFFAOYSA-N 0.000 claims description 2
- PHFMKISCNCBYKA-UHFFFAOYSA-N 3-[3-chloro-4-[5-(trifluoromethyl)pyridin-2-yl]oxyanilino]-2-oxopropanoic acid Chemical compound ClC=1C=C(NCC(C(=O)O)=O)C=CC1OC1=NC=C(C=C1)C(F)(F)F PHFMKISCNCBYKA-UHFFFAOYSA-N 0.000 claims description 2
- AQOIAODAHOWPFY-UHFFFAOYSA-N 3-[3-chloro-4-[5-(trifluoromethyl)pyridin-2-yl]oxyanilino]-3-oxopropanoic acid Chemical compound ClC1=CC(NC(=O)CC(=O)O)=CC=C1OC1=CC=C(C(F)(F)F)C=N1 AQOIAODAHOWPFY-UHFFFAOYSA-N 0.000 claims description 2
- XWLSXRYHLGGUGB-WCCKRBBISA-N 3-aminopropanoic acid;(2s)-2,5-diaminopentanoic acid Chemical compound NCCC(O)=O.NCCC[C@H](N)C(O)=O XWLSXRYHLGGUGB-WCCKRBBISA-N 0.000 claims description 2
- CZRCFAOMWRAFIC-UHFFFAOYSA-N 5-(tetradecyloxy)-2-furoic acid Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 CZRCFAOMWRAFIC-UHFFFAOYSA-N 0.000 claims description 2
- TZGKHPXUAULWOC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one;hydron;chloride Chemical compound Cl.C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 TZGKHPXUAULWOC-UHFFFAOYSA-N 0.000 claims description 2
- 108010066676 Abrin Proteins 0.000 claims description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 108700006830 Drosophila Antp Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010036449 HLA-DR10 antigen Proteins 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 2
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 2
- 108010039491 Ricin Proteins 0.000 claims description 2
- 101710192266 Tegument protein VP22 Proteins 0.000 claims description 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 2
- 108020004440 Thymidine kinase Proteins 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 2
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical group [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000002532 enzyme inhibitor Substances 0.000 claims description 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 150000002632 lipids Chemical group 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 241000700605 Viruses Species 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4671208P | 2008-04-21 | 2008-04-21 | |
| US61/046,712 | 2008-04-21 | ||
| PCT/US2009/041276 WO2009132020A2 (en) | 2008-04-21 | 2009-04-21 | Selective high-affinity polydentate ligands and methods of making such |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014043517A Division JP2014122234A (ja) | 2008-04-21 | 2014-03-06 | 選択的高親和性リガンドおよびこれらを作製する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518194A JP2011518194A (ja) | 2011-06-23 |
| JP2011518194A5 true JP2011518194A5 (enExample) | 2013-05-02 |
| JP5623384B2 JP5623384B2 (ja) | 2014-11-12 |
Family
ID=41217391
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505263A Expired - Fee Related JP5623384B2 (ja) | 2008-04-21 | 2009-04-21 | 選択的高親和性リガンドおよびこれらを作製する方法 |
| JP2014043517A Withdrawn JP2014122234A (ja) | 2008-04-21 | 2014-03-06 | 選択的高親和性リガンドおよびこれらを作製する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014043517A Withdrawn JP2014122234A (ja) | 2008-04-21 | 2014-03-06 | 選択的高親和性リガンドおよびこれらを作製する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9884070B2 (enExample) |
| EP (1) | EP2268654B1 (enExample) |
| JP (2) | JP5623384B2 (enExample) |
| CN (1) | CN102083850B (enExample) |
| AU (1) | AU2009239491B2 (enExample) |
| CA (1) | CA2721980C (enExample) |
| ES (1) | ES2613844T3 (enExample) |
| WO (1) | WO2009132020A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102762984A (zh) | 2009-11-05 | 2012-10-31 | 弗吉尼亚大学专利基金会 | 用于检测作为癌症生物标志的网蛋白-1的组合物和方法 |
| KR101939710B1 (ko) * | 2011-12-21 | 2019-01-17 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| JP6103832B2 (ja) * | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Ｅｇｆｒ結合性ペプチド |
| JP6190534B2 (ja) | 2013-08-22 | 2017-08-30 | ソニー株式会社 | 水溶性蛍光染料又は有色染料及びその使用方法 |
| WO2016011037A1 (en) * | 2014-07-14 | 2016-01-21 | Peg Biosciences, Inc. | Polymeric enkephalin prodrugs |
| CN105985524A (zh) * | 2015-02-10 | 2016-10-05 | 北京师范大学 | 针对特定靶标具备指纹识别特征的多肽复合物分子的构建方法 |
| KR102676814B1 (ko) | 2015-02-26 | 2024-06-21 | 소니그룹주식회사 | 접합 그룹을 포함하는 수용성 형광 또는 착색 염료 |
| JP6982500B2 (ja) | 2015-02-26 | 2021-12-17 | ソニーグループ株式会社 | フェニルエチニルナフタレン染料およびそれらの使用方法 |
| US10865310B2 (en) | 2015-05-11 | 2020-12-15 | Sony Corporation Of America | Ultra bright dimeric or polymeric dyes |
| US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
| CN105678112B (zh) * | 2016-02-03 | 2018-08-03 | 中国农业科学院北京畜牧兽医研究所 | 一种计算机辅助筛选小分子化合物靶标适配体的实现方法 |
| CN107580618A (zh) | 2016-04-01 | 2018-01-12 | 索尼公司 | 超亮二聚或多聚染料 |
| CN109415574B (zh) | 2016-04-01 | 2021-05-28 | 索尼公司 | 具有刚性间隔基团的超亮二聚体或聚合物染料 |
| JP7069033B2 (ja) | 2016-04-06 | 2022-05-17 | ソニーグループ株式会社 | スペーシングリンカー基を有する超明色ダイマーまたはポリマー染料 |
| WO2017197014A2 (en) | 2016-05-10 | 2017-11-16 | Sony Corporation | Compositions comprising a polymeric dye and a cyclodextrin and uses thereof |
| JP7527537B2 (ja) | 2016-05-10 | 2024-08-05 | ソニーグループ株式会社 | ペプチド骨格を有する超明色ポリマー染料 |
| AU2017264861B2 (en) | 2016-05-11 | 2021-09-23 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes |
| WO2017214165A1 (en) | 2016-06-06 | 2017-12-14 | Sony Corporation | Ionic polymers comprising fluorescent or colored reporter groups |
| US12018159B2 (en) | 2016-07-29 | 2024-06-25 | Sony Group Corporation | Ultra bright dimeric or polymeric dyes and methods for preparation of the same |
| US11524988B2 (en) | 2016-09-19 | 2022-12-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells for genetic engineering of immune cells |
| WO2018098384A1 (en) * | 2016-11-22 | 2018-05-31 | Regents Of The University Of California | Segregation modulation for immunotherapy |
| US10871459B2 (en) | 2017-02-17 | 2020-12-22 | The Regents Of The University Of California | Systems and methods for making assignments in isotope-labelled proteins using nuclear magnetic resonance data |
| WO2018156735A1 (en) * | 2017-02-22 | 2018-08-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for cancer immunotherapy |
| JP7551056B2 (ja) | 2017-10-05 | 2024-09-17 | ソニーグループ株式会社 | プログラマブルなポリマー薬物 |
| EP3691689A1 (en) * | 2017-10-05 | 2020-08-12 | Sony Corporation | Programmable dendritic drugs |
| KR102762143B1 (ko) * | 2017-11-01 | 2025-02-07 | 애로우헤드 파마슈티컬스 인코포레이티드 | 인테그린 리간드 및 그의 용도 |
| JP2021503450A (ja) | 2017-11-16 | 2021-02-12 | ソニー株式会社 | プログラム可能なポリマー薬 |
| JP7813098B2 (ja) | 2018-01-12 | 2026-02-12 | ソニーグループ株式会社 | 生物学的に活性な化合物を含む剛性間隔基を有するポリマー |
| JP2021510698A (ja) | 2018-01-12 | 2021-04-30 | ソニー株式会社 | 生物学的に活性な化合物を含むホスホアルキルリボースポリマー |
| CN111565757A (zh) | 2018-01-12 | 2020-08-21 | 索尼公司 | 包含生物活性化合物的磷酸烷基聚合物 |
| KR102742386B1 (ko) | 2018-03-19 | 2024-12-16 | 소니그룹주식회사 | 형광 신호 향상을 위한 2가 금속의 사용 |
| WO2019182766A1 (en) | 2018-03-21 | 2019-09-26 | Sony Corporation | Polymeric tandem dyes with linker groups |
| WO2019195466A1 (en) * | 2018-04-03 | 2019-10-10 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses therof |
| KR102854332B1 (ko) | 2018-06-27 | 2025-09-03 | 소니그룹주식회사 | 디옥시리보오스를 포함하는 링커 군을 갖는 중합체성 염료 |
| EP3820944A1 (en) | 2018-07-13 | 2021-05-19 | Sony Corporation | Polymeric dyes having a backbone comprising organophosphate units |
| CN109283842B (zh) * | 2018-08-02 | 2022-01-07 | 哈尔滨工程大学 | 一种无人艇航迹跟踪智能学习控制方法 |
| WO2021062176A2 (en) | 2019-09-26 | 2021-04-01 | Sony Corporation | Polymeric tandem dyes with linker groups |
| JP7816141B2 (ja) | 2019-09-30 | 2026-02-18 | ソニーグループ株式会社 | ヌクレオチドプローブ |
| WO2021127583A1 (en) * | 2019-12-20 | 2021-06-24 | Shal Technologies, Inc. | Selective high affinity ligand diagnostics and therapeutics |
| BR112022020332A2 (pt) * | 2020-04-10 | 2022-12-13 | Seagen Inc | Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune |
| EP4256078A1 (en) | 2020-12-07 | 2023-10-11 | Sony Group Corporation | Spacing linker group design for brightness enhancement in dimeric or polymeric dyes |
| CN115043898B (zh) * | 2021-03-08 | 2024-12-31 | 迈克生物股份有限公司 | 生物素化抗原衍生物及相关试剂盒和用途 |
| CN113960317A (zh) * | 2021-08-19 | 2022-01-21 | 深圳市辅酶医科技有限公司 | 一种测量生物样品中nad+浓度的生物传感器及方法 |
| WO2023138755A1 (en) * | 2022-01-18 | 2023-07-27 | NEC Laboratories Europe GmbH | Methods of vaccine design |
| EP4497432A4 (en) * | 2022-03-22 | 2025-07-30 | Bion Inc | PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF |
| WO2024059858A2 (en) * | 2022-09-15 | 2024-03-21 | Ligandal, Inc. | Approaches to discovering, analyzing, and synthesizing compounds through automated in silico experimentation |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5034223A (en) | 1986-10-09 | 1991-07-23 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| US4921690A (en) | 1986-12-29 | 1990-05-01 | City Of Hope | Method of enhancing the biodistribution of antibody for localization in lesions |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
| IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5593853A (en) | 1994-02-09 | 1997-01-14 | Martek Corporation | Generation and screening of synthetic drug libraries |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5525735A (en) | 1994-06-22 | 1996-06-11 | Affymax Technologies Nv | Methods for synthesizing diverse collections of pyrrolidine compounds |
| US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| ATE210682T1 (de) | 1996-09-03 | 2001-12-15 | Gsf Forschungszentrum Umwelt | Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern |
| US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| EP1077724A2 (en) | 1998-04-17 | 2001-02-28 | The University Of Vermont | Methods and products related to metabolic interactions in disease |
| US6217871B1 (en) | 1998-10-28 | 2001-04-17 | The Regents Of The University Of California | Antigenic epitopes with LYM-1 reactivity and uses thereof |
| GB0016361D0 (en) | 2000-07-03 | 2000-08-23 | Chiron Spa | Structure-based HCV drug design |
| US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| US20040242851A1 (en) | 2001-06-26 | 2004-12-02 | Zhenping Zhu | Bispecific antibodies that bind to vegf receptors |
| ATE423571T1 (de) | 2001-10-12 | 2009-03-15 | Schering Corp | Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten |
| AU2002335808B2 (en) | 2001-10-15 | 2009-08-27 | Ibc Pharmaceuticals | Affinity enhancement agents |
| DE10256530A1 (de) * | 2002-12-04 | 2004-06-24 | Degussa Ag | Verfahren zur Herstellung von wasserfreiem Alkalisulfid |
| US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| WO2005077065A2 (en) * | 2004-02-09 | 2005-08-25 | The Regents Of The University Of California | Selective high-affinity polydentate ligands and methods of making such |
| WO2006004910A2 (en) | 2004-06-28 | 2006-01-12 | Transtarget Inc. | Improved bispecific antibodies |
| TWI552751B (zh) | 2011-06-20 | 2016-10-11 | Ｈ 朗德貝克公司 | 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法 |
-
2009
- 2009-04-21 AU AU2009239491A patent/AU2009239491B2/en not_active Ceased
- 2009-04-21 WO PCT/US2009/041276 patent/WO2009132020A2/en not_active Ceased
- 2009-04-21 CA CA2721980A patent/CA2721980C/en active Active
- 2009-04-21 EP EP09734156.4A patent/EP2268654B1/en not_active Not-in-force
- 2009-04-21 ES ES09734156.4T patent/ES2613844T3/es active Active
- 2009-04-21 CN CN200980122906.8A patent/CN102083850B/zh not_active Expired - Fee Related
- 2009-04-21 JP JP2011505263A patent/JP5623384B2/ja not_active Expired - Fee Related
- 2009-04-21 US US12/988,801 patent/US9884070B2/en not_active Expired - Fee Related
-
2014
- 2014-03-06 JP JP2014043517A patent/JP2014122234A/ja not_active Withdrawn
-
2017
- 2017-09-13 US US15/703,848 patent/US10646502B2/en not_active Expired - Fee Related
- 2017-09-13 US US15/703,809 patent/US10292992B2/en not_active Expired - Fee Related
-
2019
- 2019-02-28 US US16/289,464 patent/US10874678B2/en not_active Expired - Fee Related
-
2020
- 2020-04-08 US US16/843,783 patent/US11285165B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roy et al. | Design and validation of fibroblast activation protein alpha targeted imaging and therapeutic agents | |
| CN102083850B (zh) | 选择性高亲和力多齿配体及其制备方法 | |
| Wang et al. | Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine− folate, a potential radiopharmaceutical for tumor imaging | |
| US20210008232A1 (en) | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer | |
| JP2009525946A (ja) | 増強された薬理学的性質を有する活性物質を送達するための方法および組成物 | |
| JP2020073472A5 (enExample) | ||
| JP2011521897A5 (enExample) | ||
| JP2010521485A5 (enExample) | ||
| JP2018503679A5 (enExample) | ||
| JP2009532338A5 (enExample) | ||
| JP2013514329A5 (enExample) | ||
| JP2007511463A5 (enExample) | ||
| JP2014501714A5 (enExample) | ||
| CN112770755A (zh) | 平台药物fl118位置7和9衍生的类似物的组成，合成，制备和应用治疗人类疾病 | |
| US11160887B2 (en) | Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
| Awasthi et al. | Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice | |
| Qiao et al. | Novel 64Cu-labeled NOTA-conjugated lactam-cyclized alpha-melanocyte-stimulating hormone peptides with enhanced tumor to kidney uptake ratios | |
| RU2010129856A (ru) | Новая вакцина для лечения связанных с микобактерией нарушений | |
| Neilio et al. | Emerging head and neck tumor targeting contrast agents for the purpose of CT, MRI, and multimodal diagnostic imaging: a molecular review | |
| Nayak et al. | Evaluation of 99mTc (I)-tricarbonyl complexes of fluoroquinolones for targeting bacterial infection | |
| Braun et al. | Synthesis, Radiolabeling, and In Vitro and In Vivo Characterization of Heterobivalent Peptidic Agents for Bispecific EGFR and Integrin αvβ3 Targeting | |
| Kim et al. | Monitoring the effect of PEGylation on polyethylenimine in vivo using nuclear imaging technique | |
| Bridger et al. | A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab ‘monoclonal antibody fragments | |
| JP2004524323A5 (enExample) | ||
| US20130237686A1 (en) | Methods and Compositions for the Rapid Synthesis of Radiometal-Labeled Probes |